Summary
This study examined early ambulatory multidrug therapy for high risk COVID 19 patients to reduce hospitalisation and death rates. The research included 869 cases, with 320 cases from April to September 2020 and 549 cases from September to December 2020. The treatment protocol involved antiviral agents, antibiotics, inhaled medications, and intravenous supplements. In the first period, 1.9% were hospitalised and 0.3% died, while in the second period, 2.6% were hospitalised and 0.18% died. The expected hospitalisation rate based on age and comorbidities was 18.5%. The study indicated an estimated 87.6% reduction in hospitalisation and a 74.9% reduction in death with early ambulatory treatment. These findings support previous research and emphasise the importance of initiating treatment early in high risk COVID 19 patients to prevent severe outcomes. The study highlights the benefits of early ambulatory treatment over late stage hospitalisation, stressing the need for prompt intervention in acutely ill patients.